Response to: 'Comment on: 'Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand et al' by Isenberg

The authors thank Professor Isenberg¹ for pointing out a drafting error on the manuscript reporting the use of the Lupus Low Disease Activity State (LLDAS) in the anifrolumab phase II trial data set.² The British Isles Lupus Assessment Group (BILAG) instrument does indeed document gastrointestinal disease activity, while Systemic Lupus Erythematosus (SLE) Disease Activity Index 2000 (SLEDAI-2K) does not. This error does not impact on the findings of the published paper, or the intended meaning of the sentence in which this error occurred, which was a discussion of the need for evidence that the physician global assessment adequately captures gastrointestinal activity in SLE.

Eric F Morand,¹ Teodora Trasieva,² Anna Berglind,² Gabor Illei,³ Raj Tummala²

¹School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Australia

²AstraZeneca, Gothenburg, Sweden

³Clinical Development, Respiratory, Inflammation and Autoimmunity, MedImmune, Gaithersburg, USA

Correspondence to Professor Eric F Morand, School of Clinical Sciences at Monash Health Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton Victoria 3168, Australia; eric.morand@monash.edu

Handling editor Josef S Smolen

Contributors EFM wrote the text, with approval from the authors.

Competing interests None declared.

Provenance and peer review Commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

To cite Morand EF, Trasieva T, Berglind A, et al. *Ann Rheum Dis* 2019;**78**:e122.

Received 1 October 2018

Revised 2 October 2018

Accepted 6 October 2018

Published Online First 29 October 2018

► <https://doi.org/10.1136/annrheumdis-2018-214468>

Ann Rheum Dis 2019;**78**:e122. doi:10.1136/annrheumdis-2018-214487

REFERENCES

- 1 Isenberg DA. Response to: 'Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand et al. *Ann Rheum Dis* 2019;**78**:e122–e122.
- 2 Morand EF, Trasieva T, Berglind A, et al. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab. *Ann Rheum Dis* 2018;**77**:706–13.